US pharmaceuticals company Pfizer has launched a neuroscience firm, called Cerevel Therapeutics, mid-to-late after it announced an end to its clinical development efforts in the field. The new company, which has been set up in partnership with investment firm Bain Capital, will focus on Parkinson's, epilepsy and other central nervous system disorders, representing Pfizer's commitment to keep a presence in the neuroscience industry. Moreover, $150m of investments in the sector will be managed by the company's new branch Pfizer Ventures, to keep an arms-length approach, rather than conducting in-house research.
US pharmaceuticals company Pfizer has launched a neuroscience firm, called Cerevel Therapeutics, almost a year after it announced an end to its clinical development efforts in the field. The new company, which has been set up in partnership with investment firm Bain Capital, will focus on Parkinson's, epilepsy and other central nervous system disorders, representing Pfizer's commitment to keep a presence in the neuroscience industry. Moreover, $150m of investments in the sector will be managed by the company's new branch Pfizer Ventures, to keep an arms-length approach, rather than conducting in-house research.